welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
UT Researcher, With CureDuchenne Support, Launches Company to Treat DMD Using CRISPR/Cas9 Technology
Eric Olson, a molecular biologist, has spent more than half his life in the lab. Now, the 62-year-old University of Texas researcher and distinguished professor is a businessman as well.
Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.
The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD).
rareRelated
-
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exon...CureDuchenne, a nonprofit global leader ...
-
Making Gene Editing a Therapeutic RealityThis review discusses current bottleneck...
-
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
-
Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a s...
-
Development of a CRISPR-based gene therapy approach targeting the large exon 45-exon 55 mutation hotspot in DMD geneGene replacement and exon skipping thera...
-
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a f...
-
Champions to CureDuchenne Gala 2018https://www.youtube.com/watch?v=cmXFoPKU...
